Hucog HP: High-Purity hCG for Precision Fertility Treatment
| Product dosage: 10000iu | |||
|---|---|---|---|
| Package (num) | Per injection | Price | Buy |
| 1 | $60.20 | $60.20 (0%) | 🛒 Add to cart |
| 2 | $57.62 | $120.40 $115.24 (4%) | 🛒 Add to cart |
| 3 | $55.90 | $180.60 $167.70 (7%) | 🛒 Add to cart |
| 4 | $54.18 | $240.80 $216.72 (10%) | 🛒 Add to cart |
| 5 | $52.46 | $301.00 $262.30 (13%) | 🛒 Add to cart |
| 6 | $51.60 | $361.20 $309.60 (14%) | 🛒 Add to cart |
| 7 | $49.88 | $421.40 $349.16 (17%) | 🛒 Add to cart |
| 8 | $48.38 | $481.60 $387.00 (20%) | 🛒 Add to cart |
| 9 | $47.78 | $541.80 $430.00 (21%) | 🛒 Add to cart |
| 10 | $47.30
Best per injection | $602.00 $473.00 (21%) | 🛒 Add to cart |
Hucog HP (Human Chorionic Gonadotropin, Highly Purified) is a pharmaceutical-grade hormone preparation designed for specialized reproductive medicine applications. Manufactured under stringent quality control standards, this highly purified form of hCG serves as a critical component in controlled ovarian stimulation protocols and other therapeutic indications. Its superior purification process ensures minimal impurities, making it particularly suitable for patients requiring precise hormonal intervention. Medical professionals rely on Hucog HP for its consistent bioavailability and predictable pharmacokinetic profile in assisted reproductive technology cycles.
Features
- Highly purified human chorionic gonadotropin (hCG) derived from recombinant DNA technology
- Available in standardized doses: 1000 IU, 2000 IU, 5000 IU, and 10,000 IU formulations
- Lyophilized powder presentation with accompanying bacteriostatic water for reconstitution
- Pre-filled syringes with ultra-fine needles for subcutaneous administration
- Manufactured in compliance with cGMP standards and international pharmacopeia requirements
- Rigorously tested for biological activity and endotoxin levels
- Single-use vials with tamper-evident packaging
- Extended shelf life with proper storage conditions
Benefits
- Facilitates final oocyte maturation in controlled ovarian stimulation cycles
- Supports luteal phase function through corpus luteum maintenance
- Enables precise timing for oocyte retrieval procedures in IVF cycles
- Provides consistent hormonal response due to high purity and standardized potency
- Reduces risk of adverse reactions associated with impurity content
- Offers flexible dosing options tailored to individual patient requirements
Common use
Hucog HP is primarily indicated for the induction of final follicular maturation and luteinization in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) program. It is also used in the treatment of selected cases of female infertility where luteal phase support is required. In male patients, Hucog HP may be prescribed for the treatment of hypogonadotropic hypogonadism to stimulate testosterone production and support spermatogenesis. Additionally, it finds application in the management of cryptorchidism not due to anatomical obstruction in pediatric patients.
Dosage and direction
For female infertility treatment: The recommended dose ranges from 5,000 to 10,000 IU administered as a single injection 24-48 hours after the last dose of follicle-stimulating hormone (FSH). For male hypogonadotropic hypogonadism: 1,000-4,000 IU administered two to three times weekly for several months. Reconstitution must be performed using the provided solvent, gently swirling without shaking to avoid denaturation. Administration is typically subcutaneous in the abdominal area, rotating injection sites. Timing of administration is critical and must be precisely coordinated with monitoring of follicular development.
Precautions
Medical supervision is mandatory throughout treatment. Patients should be monitored for ovarian hyperstimulation syndrome (OHSS), particularly those with polycystic ovary syndrome. Regular ultrasound monitoring of follicular development and estrogen level measurements are essential. Use with caution in patients with history of asthma, epilepsy, migraine, or renal/cardiac impairment. Patients should be advised about the potential risk of multiple pregnancies. Thrombboembolic events have been associated with hCG therapy—careful consideration should be given to patients with personal or family history of thrombosis.
Contraindications
Hypersensitivity to hCG or any component of the formulation; primary ovarian failure; uncontrolled thyroid or adrenal dysfunction; pituitary gland tumors; hormone-dependent tumors of the reproductive tract; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome. The product is contraindicated in cases where pregnancy is contraindicated or when normal pregnancy exists.
Possible side effect
Common reactions include injection site reactions (pain, redness, swelling), headache, restlessness, fatigue, and irritability. Less frequently reported effects include ovarian hyperstimulation syndrome (OHSS) with symptoms of abdominal pain, distension, nausea, vomiting, and diarrhea. Rare but serious adverse effects may include thromboembolic events, ectopic pregnancy, and ovarian torsion. Mild fluid retention and breast tenderness may occur due to the hormonal activity.
Drug interaction
Concomitant use with other gonadotropins may enhance the ovarian response. corticosteroids may reduce the efficacy of hCG therapy. Hormonal contraceptives may interfere with treatment outcomes. Drugs affecting pituitary function (such as dopamine agonists) may require dosage adjustment. Always inform the prescribing physician about all current medications, including over-the-counter products and herbal supplements.
Missed dose
If a dose is missed, contact the treating physician immediately. Do not double the next dose to make up for the missed administration. The timing of hCG administration is critical in fertility treatments, and even minor deviations may significantly impact treatment success. The medical team will provide specific instructions based on the treatment protocol and monitoring parameters.
Overdose
Overdose may lead to severe ovarian hyperstimulation syndrome (OHSS) characterized by rapid weight gain, abdominal pain, nausea, vomiting, and in severe cases, ascites, pleural effusion, and thromboembolic complications. Symptomatic and supportive treatment is essential, including hospitalization if severe OHSS develops. Fluid and electrolyte balance must be carefully monitored and managed. There is no specific antidote for hCG overdose.
Storage
Store unopened vials between 2°C and 8°C (36°F-46°F) in the original packaging. Protect from light. Do not freeze. After reconstitution, use immediately or within specified time limits according to manufacturer instructions (typically within 24 hours when stored at 2°C-8°C). Discard any unused portion appropriately. Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Treatment with Hucog HP must be prescribed and monitored by qualified healthcare professionals familiar with reproductive endocrinology and infertility management. Individual patient responses may vary, and treatment protocols should be tailored to specific medical circumstances. Always follow the prescribing information provided with the medication.
Reviews
Clinical studies demonstrate that Hucog HP shows comparable efficacy to other commercially available hCG preparations with excellent purity profiles. Reproductive endocrinologists report consistent luteinizing hormone (LH) surge simulation and reliable oocyte maturation outcomes. Patients appreciate the clear reconstitution instructions and minimal injection discomfort. The product has established itself as a reliable choice in fertility clinics worldwide, with particular recognition for its batch-to-batch consistency and predictable pharmacokinetic properties.